BERKELEY, Calif., June 1 /PRNewswire/ -- A splice variant microarray for clinical markers in blood was launched today by Jivan Biologics, Inc., a privately held company. Manufactured by Agilent Technologies and available as a catalogue product, Jivan’s TransExpress(TM) Whole Blood enables drug companies to discover splice isoform-based biomarkers and molecular diagnostics for human disease.
“The quest for clinically relevant biomarkers already constitutes a large portion of the half-billion-dollar-a-year microarray market,” said Subha Srinivasan, PhD, CEO and Founder of Jivan Biologics. “By detecting RNA splicing events in patient samples, TransExpress(TM) Whole Blood places Jivan at the forefront of a market shift from gene arrays to splice arrays that can detect four or more times the number of potential biomarkers and molecular diagnostics as a conventional gene array.”
With patent-pending technology for splice variant detection, TransExpress(TM) Whole Blood includes 31,765 probes for 30,042 alternately spliced sites for 19,770 splice isoforms of 2,928 human genes expressed in whole blood.
TransExpress(TM) Whole Blood works with standard hybridization kits and scanners available from Agilent Technologies and other vendors.
This announcement follows Jivan’s launch yesterday of TransExpress(TM) Whole Spliceome, the first genome-wide splice variant arrays. By comparison, TransExpress(TM) Whole Blood provides an application-based product at a lower price point, taking advantage of the fact that only a small percentage of human genes are expressed in any given tissue.
TransExpress(TM) Whole Blood can be ordered online at http://www.jivanbio.com.
Jivan Biologics empowers scientists with new insight by providing a full catalogue of splice variant arrays for drug development and biological research. Available as a service since 2001 and as catalogue products since 2003, Jivan’s flagship TransExpress(TM) arrays are the first commercial microarrays for alternate splicing.
Contact: Jonathan Bingham, 415-425-4115 Email: jbingham@jivanbio.comhttp://www.jivanbio.com
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
Jivan Biologics, Inc.
CONTACT: Jonathan Bingham, Jivan Biologics, +1-415-425-4115,jbingham@jivanbio.com
Web site: http://www.jivanbio.com/